share_log

Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bigora Sian

SEC announcement ·  Apr 13 04:54
Summary by Futu AI
On January 1, 2024, Sian Bigora, the Chief Development Officer of Processa Pharmaceuticals, Inc. (PCSA), completed a transaction involving the sale of company stock. Bigora disposed of 368 shares of common stock at a price of $2.79 per share, resulting in a total market value of $1,026.72. Following this transaction, Bigora directly holds 21,458 shares of Processa Pharmaceuticals. Additionally, Bigora has an indirect ownership of 6,668 shares through CorLyst, LLC. The transaction reflects a direct dealing by the officer and is part of the normal course of stock trading activities.
On January 1, 2024, Sian Bigora, the Chief Development Officer of Processa Pharmaceuticals, Inc. (PCSA), completed a transaction involving the sale of company stock. Bigora disposed of 368 shares of common stock at a price of $2.79 per share, resulting in a total market value of $1,026.72. Following this transaction, Bigora directly holds 21,458 shares of Processa Pharmaceuticals. Additionally, Bigora has an indirect ownership of 6,668 shares through CorLyst, LLC. The transaction reflects a direct dealing by the officer and is part of the normal course of stock trading activities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.